The conversation offered actionable insights on:

1. Why the wide-ranging effects of the IRA’s landmark policy changes will require new approaches to drug pricing, health plan design, and investment
2. How the continued focus on quality and the value of care underscores the need for strong evidence and creates new imperatives for evidence generation
3. Expected changes to community-wide healthcare, including new access to preventive services, data’s role in addressing health disparities, and the continued evolution of the health insurance landscape and access to care